Cargando…

Paroxetine overdose during pregnancy

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following paroxetine exposure in the first trimester...

Descripción completa

Detalles Bibliográficos
Autores principales: Acar, Selin, Erol, Hilal, Arslan, Elif Keskin, Uysal, Nusret, Karadaş, Barış, Temiz, Tijen Kaya, Cem Kaplan, Yusuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635663/
https://www.ncbi.nlm.nih.gov/pubmed/34868717
http://dx.doi.org/10.1080/20961790.2021.1938802
_version_ 1784608372718305280
author Acar, Selin
Erol, Hilal
Arslan, Elif Keskin
Uysal, Nusret
Karadaş, Barış
Temiz, Tijen Kaya
Cem Kaplan, Yusuf
author_facet Acar, Selin
Erol, Hilal
Arslan, Elif Keskin
Uysal, Nusret
Karadaş, Barış
Temiz, Tijen Kaya
Cem Kaplan, Yusuf
author_sort Acar, Selin
collection PubMed
description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following paroxetine exposure in the first trimester of pregnancy. However, such findings have been inconsistent. There is only one report of any overdose of an SSRI during pregnancy, and that involved escitalopram. The aim of this case report was to describe the impact of a paroxetine overdose in the first trimester of pregnancy on the health of the foetus. A 21-year-old mother of one child who was pregnant with a second child was prescribed 20 mg/day paroxetine hydrochloride for the treatment of anxiety/depression. The patient ingested 15 or 16 20-mg tablets of paroxetine hydrochloride (300–320 mg) during the 5th week of pregnancy as a suicide attempt. Within 15 min of ingestion, she was admitted to hospital and treated for intoxication. No evidence of maternal SSRI intoxication was observed after treatment. The patient consulted our teratology information service for further risk assessment regarding possible major congenital malformations following the paroxetine overdose. We were unable to find previous reports of paroxetine overdose during pregnancy in the literature. The timely administration of the overdose treatment and the lack of maternal intoxication symptoms were considered positive for the foetal well-being, and the patient was referred for perinatology and psychiatry follow-ups. A healthy, 3 500-g male infant was born at 38 weeks’ gestation, and his development at the age of 2 years was normal. This is the first reported case of paroxetine overdose during pregnancy. Comprehensive studies are needed to evaluate pregnancy outcomes after SSRI overdose. KEY POINTS: There are no reported data on paroxetine overdose during pregnancy. The aim of this case report was to describe the impact of a maternal paroxetine overdose in the first trimester of pregnancy on the health of the foetus. No evidence of maternal SSRI intoxication was observed. No congenital malformations or developmental disorders were observed in the child at 2 years of age. Comprehensive studies are needed to evaluate pregnancy outcomes following SSRI overdose.
format Online
Article
Text
id pubmed-8635663
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-86356632021-12-02 Paroxetine overdose during pregnancy Acar, Selin Erol, Hilal Arslan, Elif Keskin Uysal, Nusret Karadaş, Barış Temiz, Tijen Kaya Cem Kaplan, Yusuf Forensic Sci Res Case Report Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders. In some epidemiological studies, slightly increased risks of major malformations and cardiac malformations have been reported following paroxetine exposure in the first trimester of pregnancy. However, such findings have been inconsistent. There is only one report of any overdose of an SSRI during pregnancy, and that involved escitalopram. The aim of this case report was to describe the impact of a paroxetine overdose in the first trimester of pregnancy on the health of the foetus. A 21-year-old mother of one child who was pregnant with a second child was prescribed 20 mg/day paroxetine hydrochloride for the treatment of anxiety/depression. The patient ingested 15 or 16 20-mg tablets of paroxetine hydrochloride (300–320 mg) during the 5th week of pregnancy as a suicide attempt. Within 15 min of ingestion, she was admitted to hospital and treated for intoxication. No evidence of maternal SSRI intoxication was observed after treatment. The patient consulted our teratology information service for further risk assessment regarding possible major congenital malformations following the paroxetine overdose. We were unable to find previous reports of paroxetine overdose during pregnancy in the literature. The timely administration of the overdose treatment and the lack of maternal intoxication symptoms were considered positive for the foetal well-being, and the patient was referred for perinatology and psychiatry follow-ups. A healthy, 3 500-g male infant was born at 38 weeks’ gestation, and his development at the age of 2 years was normal. This is the first reported case of paroxetine overdose during pregnancy. Comprehensive studies are needed to evaluate pregnancy outcomes after SSRI overdose. KEY POINTS: There are no reported data on paroxetine overdose during pregnancy. The aim of this case report was to describe the impact of a maternal paroxetine overdose in the first trimester of pregnancy on the health of the foetus. No evidence of maternal SSRI intoxication was observed. No congenital malformations or developmental disorders were observed in the child at 2 years of age. Comprehensive studies are needed to evaluate pregnancy outcomes following SSRI overdose. Taylor & Francis 2021-09-28 /pmc/articles/PMC8635663/ /pubmed/34868717 http://dx.doi.org/10.1080/20961790.2021.1938802 Text en © 2021 The Author(s). Published by Taylor & Francis Group on behalf of the Academy of Forensic Science. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Acar, Selin
Erol, Hilal
Arslan, Elif Keskin
Uysal, Nusret
Karadaş, Barış
Temiz, Tijen Kaya
Cem Kaplan, Yusuf
Paroxetine overdose during pregnancy
title Paroxetine overdose during pregnancy
title_full Paroxetine overdose during pregnancy
title_fullStr Paroxetine overdose during pregnancy
title_full_unstemmed Paroxetine overdose during pregnancy
title_short Paroxetine overdose during pregnancy
title_sort paroxetine overdose during pregnancy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635663/
https://www.ncbi.nlm.nih.gov/pubmed/34868717
http://dx.doi.org/10.1080/20961790.2021.1938802
work_keys_str_mv AT acarselin paroxetineoverdoseduringpregnancy
AT erolhilal paroxetineoverdoseduringpregnancy
AT arslanelifkeskin paroxetineoverdoseduringpregnancy
AT uysalnusret paroxetineoverdoseduringpregnancy
AT karadasbarıs paroxetineoverdoseduringpregnancy
AT temiztijenkaya paroxetineoverdoseduringpregnancy
AT cemkaplanyusuf paroxetineoverdoseduringpregnancy